Renal function and outcomes in acute coronary syndrome: impact of clopidogrel
Key result
Clopidogrel added to standard therapy reduces major events across all renal function tertiles in NSTE-ACS.
- RR 0.89 (lower third), RR 0.68 (medium third), RR 0.74 (upper third)
- 95% CI 0.76-1.05 (lower), 0.56-0.84 (medium), 0.60-0.93 (upper)
- P=0.11 for heterogeneity
- n=12,253
Why the study?
Does adding clopidogrel to standard treatment reduce cardiovascular events in patients with non-ST elevation acute coronary syndromes across different levels of renal function?
Population
12,253 patients with non-ST elevation acute coronary syndromes from the CURE trial, stratified by baseline…
Comparison
Clopidogrel added to standard treatment vs Standard treatment alone
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May support clopidogrel addition across renal strata in NSTE-ACS; extends observational data but leaves open randomized confirmation in advanced CKD.
Key Points
- To evaluate the safety and efficacy of adding clopidogrel to standard therapy in patients with non-ST elevation acute coronary syndrome across varying levels of renal function.
- Retrospective analysis of 12,253 patients (97.5% of the enrolled cohort) from the randomized CURE trial.
- Renal function was estimated by baseline serum creatinine-derived glomerular filtration rate, stratifying patients into three tertiles.
- The primary outcome (composite of cardiovascular death, myocardial infarction, or stroke) was reduced by clopidogrel across all renal tertiles: lower third (RR=0.89, 95% CI 0.76–1.05), medium third (RR=0.68, 95% CI 0.56–0.84), and upper third (RR=0.74, 95% CI 0.60–0.93; P for heterogeneity = 0.11).
- Major or life-threatening bleeding with clopidogrel was not disproportionately higher in the lowest renal tertile (RR=1.12, 95% CI 0.83–1.51) versus the medium (RR=1.40, 95% CI 0.97–2.02) and upper tertiles (RR=1.83, 95% CI 1.23–2.73), though minor bleeding rose across all groups.
Study Design
Type
RCT (n=12,253)
Structured PICO
Does adding clopidogrel to standard treatment reduce cardiovascular events in patients with non-ST elevation acute coronary syndromes across different levels of renal function?
P
Population
12,253 patients with non-ST elevation acute coronary syndromes from the CURE trial, grouped by glomerular filtration rate tertiles to assess the impact of clopidogrel.
I
Intervention
Clopidogrel added to standard treatment
C
Comparator
Standard treatment alone
O
Outcome
Composite of cardiovascular death, myocardial infarction, and strokecomposite
Main Result
Effect estimate: RR 0.89 (lower third), RR 0.68 (medium third), RR 0.74 (upper third) (95% CI 0.76-1.05 (lower), 0.56-0.84 (medium), 0.60-0.93 (upper))
p-value: p=0.11 for heterogeneity
Clopidogrel provides consistent cardiovascular benefits in patients with non-ST elevation acute coronary syndromes regardless of baseline renal function, without a disproportionate increase in major bleeding in those with chronic kidney disease.
Cite This Study
Keltai et al. (2007) conducted an RCT in non-ST elevation acute coronary syndromes (n=12,253). Clopidogrel vs. Standard treatment was evaluated on cardiovascular death, myocardial infarction, stroke combined (RR 0.89 (lower third), RR 0.68 (medium third), RR 0.74 (upper third), 95% CI 0.76-1.05 (lower), 0.56-0.84 (medium), 0.60-0.93 (upper), p=0.11 for heterogeneity). Adding clopidogrel to standard treatment in non-ST elevation acute coronary syndrome reduced cardiovascular death, MI, or stroke across all renal function tertiles (P for heterogeneity=0.11).